BioSpace

Bonus: Q4 2025 Job Market Update

Deals Roll at JPM26, Policy Front and Center, IPOs Are Back, FDA Stays Busy

The BioSpace podcast delivers updates from JPM week, focusing on key deals, policy shifts, and industry sentiment. AbbVie's potential $5 billion commitment for a PD-1 VEGF bi-specific from RemeGen and Novartis's $1.5 billion Alzheimer's deal with SciNeuro Pharmaceuticals highlight the trend of seeking innovation from C...

From Nuclear Winter to Renewal: Biotech Investing for 2026

Novo Launches Oral Obesity Pill, Lilly Targets Lofty Revenue, FDA and M&A in Focus

Inside the 2026 Biotech Landscape: Innovation, Investment and Global Momentum

Lilly’s Triple Triumph, Prasad’s COVID Error, J&J’s Surprise Voucher, M&A Targets

Beyond the Gluten-Free Diet: A New Era in Celiac Disease Treatment

Weight Loss Waves, Pazdur’s Exit and FDA Instability, New Neuro Breakthroughs

New Approach Methodologies: Redefining Animal Testing Alternatives

Prasad’s Leaked FDA Memo, Alzheimer’s Ups and Downs, Next-Gen Obesity Drugs

Billions More in M&A, Another Bidding War and More FDA Drama

How Biotech Funding is Changing Executive Search and Hiring Processes

Pfizer Wins Metsera, Trump Strikes GLP-1 Pricing Deal, FDA Awards More Priority Vouchers

Thoughtful Tech: How Removing Technological Burdens Can Improve Clinical Trial Compliance and Patient Experience

Pfizer and Novo Battle Over Metsera, Tidmarsh Fights FDA Exit, UniQure and Sarepta Face Setbacks

Innovation, Resilience, and the Future of Global Manufacturing

Novartis’ Big Buy, Q3 Earnings, Regeneron’s Dropped Cell Therapy, More

How Supply Chain Turbulence is Reshaping Biotech Strategy

Novo Board Upended, ESMO Excitement, FDA Awards, Replimune’s U-Turn

Cost Control to Capability Building: Rethinking Supply and Strategy in Pharma